ProKidney Corp.
ProKidney Corp., a clinical-stage biotechnology company, develops a cell therapy platform for the treatment of multiple chronic kidney diseases in the United States. Its lead product candidate, rilparencel, includes autologous selected renal cells (SRC) in Phase 3 and Phase 2 clinical studies in subjects with moderate to severe chronic kidney disease and diabetes. The company also develops a cryo… Read more
ProKidney Corp. (PROK) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.084x
Based on the latest financial reports, ProKidney Corp. (PROK) has a cash flow conversion efficiency ratio of -0.084x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-26.60 Million) by net assets ($318.34 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
ProKidney Corp. - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how ProKidney Corp.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
ProKidney Corp. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ProKidney Corp. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
SENCO GOLD LTD
NSE:SENCO
|
0.015x |
|
Voyager Therapeutics Inc
NASDAQ:VYGR
|
-0.141x |
|
Zhuzhou Feilu High-Tech Materials Co Ltd
SHE:300665
|
0.019x |
|
Nepes Corporation
KQ:033640
|
0.041x |
|
Medical Facilities Corporation
PINK:MFCSF
|
0.126x |
|
Genus Power Infrastructures Limited
NSE:GENUSPOWER
|
-0.083x |
|
Climb Bio Inc
NASDAQ:CLYM
|
-0.097x |
|
Simulations Plus Inc
NASDAQ:SLP
|
0.033x |
Annual Cash Flow Conversion Efficiency for ProKidney Corp. (2019–2024)
The table below shows the annual cash flow conversion efficiency of ProKidney Corp. from 2019 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $401.64 Million | $-126.35 Million | -0.315x | -36.68% |
| 2023-12-31 | $391.34 Million | $-90.07 Million | -0.230x | -50.76% |
| 2022-12-31 | $504.94 Million | $-77.09 Million | -0.153x | +91.83% |
| 2021-12-31 | $26.92 Million | $-50.30 Million | -1.869x | +26.80% |
| 2020-12-31 | $9.86 Million | $-25.18 Million | -2.553x | -52690.69% |
| 2019-12-31 | $15.88 Million | $-76.81K | -0.005x | -- |